Alicia Morgan, MD

home / authors / alicia-morgan-md

Articles

Alicia Morgans, MD, MPH, member, faculty of medicine, Harvard Medical School, medical director, Survivorship Program, Dana-Farber Cancer Institute

Dr. Morgans on the Current Treatment Landscape For mHSPC

Alicia Morgan, MD
January 18th 2023

Alicia Morgans, MD, MPH, discusses current androgen deprivation therapy combinations and the investigation of radiopharmaceutical combinations for metastatic hormone-sensitive prostate cancer.

Read More

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

Alicia Morgan, MD
February 7th 2018

Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.

Read More

Dr. Morgan Discusses the Impact of PARP Inhibitors in Prostate Cancer

Dr. Morgan Discusses the Impact of PARP Inhibitors in Prostate Cancer

Alicia Morgan, MD
February 1st 2018

Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.

Read More

Dr. Morgan on Enrolling Patients With Prostate Cancer onto Clinical Trials

Dr. Morgan on Enrolling Patients With Prostate Cancer onto Clinical Trials

Alicia Morgan, MD
January 20th 2018

Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.

Read More

Dr. Morgan on the Role of PARP Inhibitors in Prostate Cancer

Dr. Morgan on the Role of PARP Inhibitors in Prostate Cancer

Alicia Morgan, MD
January 17th 2018

Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.

Read More

Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer

Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer

Alicia Morgan, MD
December 21st 2017

Alicia Morgan, MD, Mather Hospital, discusses the role of olaparib (Lynparza) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data